These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 25720623)
1. Bioresorbable vascular scaffolds in daily clinical practice: is the essential really invisible to the eyes? Abizaid A; Costa JR; Gibson CM J Am Coll Cardiol; 2015 Mar; 65(8):802-804. PubMed ID: 25720623 [No Abstract] [Full Text] [Related]
2. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622 [TBL] [Abstract][Full Text] [Related]
3. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design. Woudstra P; Grundeken MJ; Kraak RP; Hassell ME; Arkenbout EK; Baan J; Vis MM; Koch KT; Tijssen JG; Piek JJ; de Winter RJ; Henriques JP; Wykrzykowska JJ Am Heart J; 2014 Feb; 167(2):133-40. PubMed ID: 24439973 [TBL] [Abstract][Full Text] [Related]
4. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961 [TBL] [Abstract][Full Text] [Related]
5. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial. Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627 [TBL] [Abstract][Full Text] [Related]
6. Coronary artery aneurysms formation within Everolimus-eluting stents and bioresorbable vascular scaffolds. Lee WC; Chung WJ; Fang HY; Wu CJ Int J Cardiol; 2016 Mar; 206():58-60. PubMed ID: 26774833 [No Abstract] [Full Text] [Related]
7. Stent selection and antiplatelet therapy duration: one size does not fit all. Kandzari DE J Am Coll Cardiol; 2015 Mar; 65(8):816-819. PubMed ID: 25720625 [No Abstract] [Full Text] [Related]
8. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies. Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538 [TBL] [Abstract][Full Text] [Related]
9. Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. Ielasi A; Latib A; Naganuma T; Cortese B; Sato K; Miyazaki T; Panoulas VF; Tespili M; Colombo A Int J Cardiol; 2014 May; 173(3):513-4. PubMed ID: 24717326 [No Abstract] [Full Text] [Related]
10. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial. Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027 [TBL] [Abstract][Full Text] [Related]
11. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532 [TBL] [Abstract][Full Text] [Related]
12. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924 [TBL] [Abstract][Full Text] [Related]
13. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495 [TBL] [Abstract][Full Text] [Related]
14. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. Bangalore S; Guo Y; Samadashvili Z; Blecker S; Xu J; Hannan EL N Engl J Med; 2015 Mar; 372(13):1213-22. PubMed ID: 25775087 [TBL] [Abstract][Full Text] [Related]
15. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310 [TBL] [Abstract][Full Text] [Related]
16. Bioresorbable Stents in PCI. Lindholm D; James S Curr Cardiol Rep; 2016 Aug; 18(8):74. PubMed ID: 27312934 [TBL] [Abstract][Full Text] [Related]